PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) presents at metastatic stage in over 50% of patients. With a survival rate of just 2.7% for patients presenting with distant disease, it is imperative to uncover novel mechanisms capable of suppressing metastasis in PDAC. Previously, we reported that the loss...
Main Authors: | Ann E. Zeleniak, Wei Huang, Melissa L. Fishel, Reginald Hill |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-01-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558617303548 |
Similar Items
-
Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
by: Hossein Taghizadeh, et al.
Published: (2020-07-01) -
The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
by: Demi S. Houg, et al.
Published: (2018-06-01) -
Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma
by: Georgios A. Kaissis, et al.
Published: (2020-03-01) -
Chemokines and their receptors in the metastatic behaviour of human pancreatic ductal adenocarcinoma
by: Marchesi, Federica
Published: (2006) -
The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma
by: Jorge Melendez-Zajgla, et al.
Published: (2021-06-01)